Imperial College London
Portrait Picture

DrAdamFrampton

Faculty of Medicine, Department of Surgery & Cancer

Honorary Clinical Lecturer
 
 
 
//

Contact

 

+44 (0)20 7594 2125a.frampton

 
 
//

Location

 

4005Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Macias:2022:10.1136/gutjnl-2022-327099,
author = {Macias, RIR and Cardinale, V and Kendall, TJ and Avila, MA and Guido, M and Coulouarn, C and Braconi, C and Frampton, AE and Bridgewater, J and Overi, D and Pereira, SP and Rengo, M and Kather, JN and Lamarca, A and Pedica, F and Forner, A and Valle, JW and Gaudio, E and Alvaro, D and Banales, JM and Carpino, G},
doi = {10.1136/gutjnl-2022-327099},
journal = {Gut},
pages = {1669--1683},
title = {Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions.},
url = {http://dx.doi.org/10.1136/gutjnl-2022-327099},
volume = {71},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Cholangiocarcinoma (CCA) is a malignant tumour arising from the biliary system. In Europe, this tumour frequently presents as a sporadic cancer in patients without defined risk factors and is usually diagnosed at advanced stages with a consequent poor prognosis. Therefore, the identification of biomarkers represents an utmost need for patients with CCA. Numerous studies proposed a wide spectrum of biomarkers at tissue and molecular levels. With the present paper, a multidisciplinary group of experts within the European Network for the Study of Cholangiocarcinoma discusses the clinical role of tissue biomarkers and provides a selection based on their current relevance and potential applications in the framework of CCA. Recent advances are proposed by dividing biomarkers based on their potential role in diagnosis, prognosis and therapy response. Limitations of current biomarkers are also identified, together with specific promising areas (ie, artificial intelligence, patient-derived organoids, targeted therapy) where research should be focused to develop future biomarkers.
AU  - Macias,RIR
AU  - Cardinale,V
AU  - Kendall,TJ
AU  - Avila,MA
AU  - Guido,M
AU  - Coulouarn,C
AU  - Braconi,C
AU  - Frampton,AE
AU  - Bridgewater,J
AU  - Overi,D
AU  - Pereira,SP
AU  - Rengo,M
AU  - Kather,JN
AU  - Lamarca,A
AU  - Pedica,F
AU  - Forner,A
AU  - Valle,JW
AU  - Gaudio,E
AU  - Alvaro,D
AU  - Banales,JM
AU  - Carpino,G
DO  - 10.1136/gutjnl-2022-327099
EP  - 1683
PY  - 2022///
SP  - 1669
TI  - Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions.
T2  - Gut
UR  - http://dx.doi.org/10.1136/gutjnl-2022-327099
UR  - https://www.ncbi.nlm.nih.gov/pubmed/35580963
VL  - 71
ER  -
Download